DOI QR코드

DOI QR Code

Adipo-R1 and Adipo-R2 Expression in Colorectal Adenomas and Carcinomas

  • Ayyildiz, Talat (Department of Gastroenterology, Medical Faculty, Ondokuz Mayis University) ;
  • Dolar, Enver (Department of Gastroenterology, Medical Faculty, Uludag University) ;
  • Ugras, Nesrin (Department of Pathology, Medical Faculty, Uludag University) ;
  • Eminler, Ahmet Tarik (Department of Gastroenterology, Medical Faculty, Sakarya University) ;
  • Erturk, Banu (Department of Internal Medicine, Medical Faculty, Erciyes University) ;
  • Adim, Saduman Balaban (Department of Pathology, Medical Faculty, Uludag University) ;
  • Yerci, Omer (Department of Pathology, Medical Faculty, Uludag University)
  • Published : 2015.02.04

Abstract

Background: Human adiponectin (ApN), a 30 kDa glycoprotein of 244-amino acids which is predominantly produced by adipocytes, exerts its effects via two receptors, namely adiponectin receptor-1 (adipo-R1) and adiponectin receptor-2 (adipo-R2) with differential binding affinity to globular adiponectin. Adiponectin receptor expression has been studied in several cancer tissues. However, there are no studies of colorectal adenomas which are considered to be precursors for colorectal carcinoma (CRC). Objectives: In the present study, the expression of adipo-R1 and adipo-R2 was investigated immunohistochemically in colorectal adenomas and colorectal carcinoma tissues in an attempt to determine associations with these tumors. Materials and Methods: The study enrolled 50 CRC patients with tumor resection and 82 patients who were diagnosed with adenomatous polyps, classified as negative for neoplasia, low-grade dysplasia (L-GD) or high- grade dysplasia (H-GD). Results: Expression of both adipo-R1 and adipo-R2 was found to be significantly lower in the CRCs than in colorectal adenomas (tubular and tubulovillous, p=0.009 and p<0.001, respectively). Adipo-R1 and adipo-R2 expression was also significantly lower in the CRC group when compared with the groups of patients with low grade dysplasia, high-grade dysplasia or no neoplasia (p=0.012 and p<0.001, respectively). In addition, it was observed that adipo-R2 expression was generally positive in the non-neoplastic group irrespective of the adipo-R2 expression. In the L-GD, H-GD and CRC groups, the adipo-R2 result was positive whenever adipo-R1 result was positive but some patients with negative adipo-R1 had positive adipo-R2 (p<0.001, p=0.004, p<0.001, respectively). Conclusions: This study indicated that ApN may play a role in the progression of colorectal adenomatous polyps to carcinoma through actions on adipo-R1 and adipo-R2 receptors.

Keywords

Adiponectin;adipoR1;adipoR2;colorectal carcinoma;polyps;progression

References

  1. Ayyildiz T, Dolar E, Ugras N, Adim SB, Yerci O (2014a). Association of adiponectin receptor (adipo-r1/-r2) expression and colorectal cancer. Asian Pac J Cancer Prev, 15, 9385-90. https://doi.org/10.7314/APJCP.2014.15.21.9385
  2. Ayyildiz T, Dolar E, Ugras N, et al (2014b). Lack of any prognostic relationship between adiponectin receptor (Adipo R1/R2) expression for early/advanced stage gastric cancer. Asian Pac J Cancer Prev, 15, 4711-16. https://doi.org/10.7314/APJCP.2014.15.11.4711
  3. Barresi V, Grosso M, Giuffre G, Tuccari G, Barresi G (2009a). The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol, 62, 705-9. https://doi.org/10.1136/jcp.2009.066175
  4. Barresi V, Tuccari G, Barresi G (2009b). Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology, 41, 533-8. https://doi.org/10.1080/00313020903071553
  5. Bobe G, Murphy G, Rogers CJ, et al (2010). Serum adiponectin, leptin,C-peptide, homocysteine, and colorectal adenoma recurrence in the Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev, 19, 1441-52. https://doi.org/10.1158/1055-9965.EPI-09-1082
  6. Brakenhielm E, Veitonmaki N, Cao R, et al (2004). Adiponectininduced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 101, 2476-81. https://doi.org/10.1073/pnas.0308671100
  7. Bresalier RS (2010). Colorectal cancer. In'Sleisenger and Fordtran's Gastrointestinal and Liver Disease' Eds Feldman M, Friedman LS and Brandt LJ. Saunders, an imprint of Elsevier Inc. Philadelphia, pp 2191-239.
  8. Canhoroz M, Kanat O, Saraydaroglu O, et al (2014). Clinical significance of adiponectin expression in colon cancer patients. J Cancer Res Ther, 10, 347-53 https://doi.org/10.4103/0973-1482.136634
  9. Chronis A, Thomopoulos K, Sapountzis A, et al (2011). Adiposity factors are not related to the presence of colorectal adenomas. Clin Exp Gastroenterol, 4, 257-61.
  10. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 33, 547-94. https://doi.org/10.1210/er.2011-1015
  11. Danese E, Minicozzi AM, Montagnana M, et al (2013). Lack of an association between circulating adiponectin levels and risk of colorectal adenoma. Clin Lab, 59, 211-4.
  12. Goldfine AB, Kahn CR (2003). Adiponectin: linking the fat cell to insulin sensitivity. Lancet, 362, 1431-2. https://doi.org/10.1016/S0140-6736(03)14727-7
  13. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8. https://doi.org/10.7314/APJCP.2012.13.1.395
  14. Hebbard L, Ranscht B (2014). Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab, 28, 59-69. https://doi.org/10.1016/j.beem.2013.11.005
  15. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405. https://doi.org/10.7314/APJCP.2014.15.1.397
  16. Kim AY, Lee YS, Kim KH, et al (2010). Adiponectin represses colon cancer cell proliferation via AdipoR1-and-R2-mediated AMPK activation. Mol Endocrinol, 24, 1441-52. https://doi.org/10.1210/me.2009-0498
  17. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of CRC. Cancer Epidemiol Biomarkers Prev, 15, 401-2. https://doi.org/10.1158/1055-9965.EPI-05-0836
  18. Lysaght J, van der Stok EP, Allott EH, et al (2011). Proinflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett, 312, 62-72. https://doi.org/10.1016/j.canlet.2011.07.034
  19. Matsuzawa Y, Shimomura I, Kihara S, et al (2003). Importance of adipocytokines in obesityrelated diseases. Horm Res, 3, 56-9.
  20. Ouchi N, Kihara S, Arita Y, et al (1999). Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-6. https://doi.org/10.1161/01.CIR.100.25.2473
  21. Ouchi N, Kihara S, Arita Y, et al (2000). Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFkappaB signaling through a cAMP-dependent pathway. Circulation, 102, 1296-301. https://doi.org/10.1161/01.CIR.102.11.1296
  22. Ouchi N, Kihara S, Arita Y, et al (2001). Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocytederived macrophages. Circulation, 103, 1057-63. https://doi.org/10.1161/01.CIR.103.8.1057
  23. Otake S, Takeda H, Suzuki Y, et al (2005). Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res, 11, 3642-6. https://doi.org/10.1158/1078-0432.CCR-04-1868
  24. Saxena A, Baliga MS, Ponemone V, et al (2013). Mucus and adiponectin deficiency: role inchronic inflammation-induced colon cancer. Int J Colorectal Dis, 28, 1267-79. https://doi.org/10.1007/s00384-013-1664-2
  25. Siegel R, Desantis C, Jemal A (2014). Colorectal cancer statistics, 2014. CA Cancer J Clin, 64, 104-17 https://doi.org/10.3322/caac.21220
  26. Sugiyama M, Takahashi H, Hosono K, et al (2009). Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol, 34, 339-44.
  27. Tilg H, Moschen AR (2014). Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol, 28, 599-610. https://doi.org/10.1016/j.bpg.2014.07.006
  28. Wei EK, Giovannucci E, Fuchs CS, Willet WC, Mantzoros CS (2005). Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 97, 1688-94. https://doi.org/10.1093/jnci/dji376
  29. Yamauchi T, Kamon J, Ito Y, et al (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-9. https://doi.org/10.1038/nature01705
  30. Yamauchi T, Iwabu M, Okada-Iwabu M, Kadowaki T (2014). Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab, 28, 15-23. https://doi.org/10.1016/j.beem.2013.09.003
  31. Yoneda K, Tomimoto A, Endo H, et al (2008). Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep, 20, 479-83.
  32. Zauber AG, Winawer SJ, O'Brien MJ, et al (2012). Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med, 366, 687-96. https://doi.org/10.1056/NEJMoa1100370

Cited by

  1. Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6923